By Adria Calatayud 
 

GlaxoSmithKline PLC (GSK.LN) said Wednesday that ViiV Healthcare, its HIV venture with Pfizer Inc. (PFE), has met primary endpoint in a phase 3 clinical trial.

The trial demonstrated the ability to control HIV with a two-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a three-drug regimen containing tenofovir alafenamide fumarate, the U.K. pharmaceutical company said.

The study was conducted to assess whether adults living with HIV who had maintained viral suppression for at least six months on a regimen of at least three drugs containing tenofovir alafenamide fumarate were able to maintain similar rates of viral suppression after switching to the two-drug regimen, Glaxo said.

 

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

 

(END) Dow Jones Newswires

July 10, 2019 02:39 ET (06:39 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Gsk.